Print PDF

Sheppard Mullin Advises Tiziana Life Sciences on Follow-on Pubic Offering

Client to Use Net Proceeds to Expedite Clinical Development for Potential COVID-19 Treatment

Sheppard Mullin advised Tiziana Life Sciences plc (Nasdaq: TLSA) (AIM: TILS), a U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, including COVID-19, with its underwritten follow-on public offering of American Depositary Shares on the NASDAQ Global Market, raising approximately $10 million.

Partner Jeffrey Fessler and associate Justin Anslow represented Tiziana Life Sciences in the public offering.

Click here to read the press release.


Practice Areas


Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.